Last updated: February 20, 2026
INFUVITE PEDIATRIC is a multivitamin supplement designed for pediatric use, providing essential nutrients for infants and young children. Several companies hold manufacturing or distribution rights for this product across different markets.
Major Suppliers and Manufacturers
| Supplier/Manufacturer |
Region |
Key Details |
| Fresenius Kabi |
Global (primarily U.S., Europe) |
Manufactures INFUVITE PEDIATRIC for various markets. Focuses on sterile compounding and hospital supplies. |
| West-Ward Pharmaceuticals |
United States |
Licensed distributor of INFUVITE PEDIATRIC in North America. Known for hospital pharmaceuticals. |
| Meso Scale Diagnostics |
United States |
Provides related pediatric nutritional assays, sometimes supplies components for diagnostic use linked to nutritional products. |
| Contract manufacturing organizations (CMOs) |
Global |
Certain regional distributors may source through third-party CMOs depending on local regulations and supply demands. |
Supply Channels and Distribution
- Hospitals and clinics: Major procurement occurs through hospital systems, with direct orders from brand owners or authorized distributors.
- Pharmaceutical wholesalers: Distribute to pharmacy chains, hospital suppliers, and specialty care providers.
- Regional distributors: Local companies often hold exclusive rights in specific countries or regions, especially in Asia, Latin America, and Africa.
- Online and specialty suppliers: Some niche vendors may source through authorized distributors or importers.
Regulatory and Licensing Factors
- INFUVITE PEDIATRIC is typically approved by the FDA (U.S. Food and Drug Administration) and equivalent authorities in other regions.
- Manufacturers require licensing agreements, which specify manufacturing standards, quality controls, and distribution rights.
- Variations in formulations or packaging may reflect regional regulatory standards, influencing supplier sourcing.
Market Dynamics
- The global pediatric nutritional supplement segment is projected to grow at a compound annual growth rate (CAGR) of approximately 6.2% from 2022 to 2030 [1].
- Supply chain disruptions caused by the COVID-19 pandemic have led to increased reliance on regional suppliers and manufacturers.
- There is heightened demand for sterile, hospital-grade formulations, favoring suppliers with capabilities for aseptic manufacturing.
Key Takeaways
- Multiple regional suppliers hold rights to INFUVITE PEDIATRIC, including Fresenius Kabi and West-Ward Pharmaceuticals.
- Distribution involves hospitals, wholesalers, and specialty online vendors.
- Regulatory approval and licensing shape supplier options and regional availability.
- Supply chain considerations have increased focus on local manufacturing and diversified sources.
FAQs
Q1: Which companies manufacture INFUVITE PEDIATRIC globally?
Fresenius Kabi is the primary manufacturer for several markets. West-Ward Pharmaceuticals acts as a major distributor in North America.
Q2: How do regional regulations affect suppliers?
Regulatory standards influence formulation, packaging, and licensing, which can restrict or expand supplier options in specific countries.
Q3: Are there alternative sources of INFUVITE PEDIATRIC?
Yes, regional distributors and authorized online vendors may provide alternative sourcing depending on licensing agreements and regulatory approvals.
Q4: What impacts supply chain stability for INFUVITE PEDIATRIC?
Pandemic-related disruptions, manufacturing capacity, and regional regulatory changes can affect supply continuity.
Q5: What is the growth outlook for pediatric nutritional supplements?
The segment is expected to grow at a CAGR of approximately 6.2% through 2030, driven by increasing awareness and demand for infant nutrition.
References
[1] Research and Markets. (2022). Pediatric Nutritional Supplements Market Forecast. https://www.researchandmarkets.com
